共查询到20条相似文献,搜索用时 15 毫秒
1.
《Pharmaceutical development and technology》2013,18(6):671-676
AbstractNocodazole (NCD) has more carcinogenic effect than similar drugs. Moreover, it has low drug release time and high particle size. Solid Lipid Nanoparticles (SLNs) have been evaluated for decrease in particle size and therefore increase in drug release time, for such drugs. In this study, NCD has been successfully incorporated into SLNs systems and remained stable for a period of 90 days. NCD structure related to the chemical nature of solid lipid is a key factor to decide whether anticarcinogenic agent will be incorporated in the long term and for a controlled optimization of active ingredient incorporation and loading, intensive characterization of the physical state of the lipid particles were highly essential. Thus, NMR, FT-IR, DSC (for thermal behavior) analyses were performed and the results did not indicate any problem on stability. Moreover, SLNs were decreased size of NCD in addition to increase in time of the drug release. After SLN preparation, particle size, polydispersity index, electrical conductivity and zeta potential were measured and drug release from NCD-loaded SLNs were performed. These values seem to be of the desired range. 相似文献
2.
姜黄素固体脂质纳米粒的制备及表征 总被引:6,自引:0,他引:6
目的:制备姜黄素(Cur)固体脂质纳米粒(SLN)。方法:用薄膜超声法制备Cur-SLN,以mcur:m单硬脂酸甘油酯、m单硬脂酸甘油酯:m卵磷脂、聚山梨酯-80质量浓度、超声时间为考察因素,以包封率为指标,用正交试验优选处方,并考察其粒径分布、Zeta电位。结果:当mcur:m单硬脂酸甘油酯=1:3、m单硬脂酸甘油酯:m卵磷脂=1:2.5、聚山梨酯-80质量浓度2.5%、超声时间12min时,所制得的Cur-SLN平均粒径为(145.6±5)nm,Zeta电位为(-31.9±1.5)mV,包封率为(97.42±0.39)%,载药量为(7.92±0.05)%。结论:采用薄膜-超声法制备Cur-SLN可行,为开发姜黄素新型给药系统提供试验依据。 相似文献
3.
The study describes the development of stealth solid lipid nanoparticles (SLNs) as colloidal carriers for silibinin, a drug with very low solubility. Stealth SLNs were constituted mainly of bioacceptable and biodegradable lipids, such as stearic acid and surfactant Brij 78 (polyoxyethylene 20 stearyl ether) and can incorporate amounts of silibinin up to 7.55%. Stealth-loaded SLNs were in the nanometer size range. Thermal analysis (differential scanning calorimetry) showed that silibinin was dispersed in the stealth SLNs at an amorphous state. Release of silibinin from stealth SLNs was very slow. Stealth SLNs were stable without precipitation of silibinin on storage conditions and can be proposed for their parenteral administration. 相似文献
4.
This article describes the development of solid lipid nanoparticles (SLN) as colloidal carriers for cloricromene. Nanoparticles were prepared by the microemulsion or precipitation technique. In vitro drug release profile from SLN was studied under various experimental conditions mimicking some body fluids. The drug release rate of drug at pH 7.4 and human plasma is high. In plasma, after 15 min, about 70% of drug was released. The cloricromene that was not released within 4 hr was found in the SLN. This result suggests that this colloidal system could be useful for targeted drug delivery to the central nervous system after intravenous administration. 相似文献
5.
Solid lipid nanoparticles (SLN) are an alternative colloidal carrier system for controlled drug delivery. However, only a few have been studied regarding the incorporation of peptides into SLN, due to the hydrophilic peptide not easy to enter the lipophilic matrix of SLN. In the present report, peptide-loaded solid lipid nanoparticles were prepared by a novel solvent diffusion method in an aqueous system. The model peptide gonadorelin was incorporated to study the entrapment efficiency, size, zeta potential (charge) and drug delivery characterization. Gonadorelin and monostearin were dissolved in acetone and ethanol at 50 degrees C in water bath, the resultant organic solution was poured into an aqueous containing 1% polyvinyl alcohol (PVA) under mechanical agitation. The peptide-loaded solid lipid nanoparticles were quickly produced and separated by centrifugation. The average volume diameter of gonadorelin-loaded SLN is 421.7 nm and the zeta potential of SLN is -21.1 mV dispersed in distilled water. Up to 69.4% of gonadorelin can be incorporated. In vitro release of gonadorelin from SLN is slow. In the test solution of a 0.1N hydrochloric acid for 2h and then transferred in a pH 6.8 phosphate buffer (simulative gastrointestinal fluid), the drug-release behavior from SLN suspension exhibited a biphasic pattern. After burst drug-release at the first 6h at a percentage of 24.4% of loaded gonadorelin, a distinctly prolonged release over a monitored period of 12 days was observed and nearly 3.81% of drug was released in each day. In the test solution of a pH 6.8 phosphate buffer (simulative intestinal fluid), the drug-release rate from SLN was similar to that in the simulative gastrointestinal fluid. Further, a novel preparation method in the present research for peptide-loaded SLN was established. These results also demonstrate the principle suitability of SLN as a prolonged release formulation for hydrophilic peptide drugs. 相似文献
6.
目的:以聚乙二醇单硬脂酸酯表面修饰材料结合到固体脂质纳米粒(solid lipid nanoparticles,SLN),以雷公藤内酯醇(triptolide,TPL)为模型药,制备一种具有良好亲水亲脂性的雷公藤内酯醇固体脂质纳米粒。方法:采用熔融-乳化法制备固体脂质纳米粒。通过单因素考察、中心复合设计(central composite design,CCD),考察脂质材料、聚山梨醇酯-80和PEG-stearate(PEG-SA)三个因素对TPL-SLN粒径、包封率和载药量的影响。通过透射电镜、热分析和X-射线衍射考察TPL-SLN的理化性质,并考察其固体脂质纳米粒的稳定性以及体外释放情况。用MTT法测定其对人正常肝L02细胞和肝癌细胞HepG2的增殖抑制作用并计算其IC50。结果:最优的处方:脂质材料为7.5%,聚山梨醇酯80(Tween 80)为2%和PEG-SA为2%,其粒径(193.43±6.07)nm,包封率(87.63±0.09)%,载药量(0.33±0.01)%。透射电镜观察所制备的纳米粒的形态近似于球形,DSC分析和X-射线衍射证实TPL以非晶型的形式存在于固体脂质纳米粒中。稳定性考察发现纳米粒粒径在一个月的贮存期基本没有变化(P>0.05),体外释放表明TPL-SLN具有体外缓释特性。TPL-SLN对肿瘤细胞的抑制作用强于正常肝细胞。结论:雷公藤内酯醇聚乙二醇修饰固体脂质纳米粒有望开发为临床口服用药新剂型。 相似文献
7.
Wang D Wang X Li X Ye L 《PDA journal of pharmaceutical science and technology / PDA》2008,62(1):56-65
This work investigated the potential of solid lipid nanoparticles (SLNs) to improve oral bioavailablity and tissue uptake of a poorly soluble drug, alpha-Asarone. Ultrasonic homogenization method was employed to prepare alpha-Asarone-loaded SLNs (alpha-Asarone-SLNs). Particle size and distribution, pH, viscosity, drug incorporation and zeta potential of the SLNs were investigated. Pharmacokinetic study of oral administration to male rats at 10 mg/Kg suggested that the relative bioavailability of alpha-Asarone was significantly improved in alpha-Asarone-SLN group compared to alpha-Asarone solution group. Comparison of alpha-Asarone-SLN to alpha-Asarone control solution for alpha-Asarone concentrations in rat tissue showed an increased uptake of alpha-Asarone in brain and lung for the ARE-SLN group. These results indicate that alpha-Asarone-SLNs significantly enhance the absorption and tissue distribution of alpha-Asarone. SLNs offer a new approach to improve the oral bioavailability of poorly soluble drugs. 相似文献
8.
Preparation and characterization of n-dodecyl-ferulate-loaded solid lipid nanoparticles (SLN) 总被引:3,自引:0,他引:3
Souto EB Anselmi C Centini M Müller RH 《International journal of pharmaceutics》2005,295(1-2):261-268
Solid lipid nanoparticles (SLN) containing a novel potential sunscreen n-dodecyl-ferulate (ester of ferulic acid) were developed. The preparation and stability parameters of n-dodecyl-ferulate-loaded SLN have been investigated concerning particle size, surface electrical charge (zeta potential) and matrix crystallinity. The chemical stability of n-dodecyl-ferulate at high temperatures was also assessed by thermal gravimetry analysis. For the selection of the appropriated lipid matrix, chemically different lipids were melted with 4% (m/m) of active and lipid nanoparticles were prepared by the so-called high pressure homogenization technique. n-Dodecyl-ferulate-loaded SLN prepared with cetyl palmitate showed the lowest mean particle size and polydispersity index, as well as the highest physical stability during storage time of 21 days at 4, 20 and 40 degrees C. These colloidal dispersions containing the sunscreen also exhibited the common melting behaviour of aqueous SLN dispersions. 相似文献
9.
Potta SG Minemi S Nukala RK Peinado C Lamprou DA Urquhart A Douroumis D 《Journal of microencapsulation》2011,28(1):74-81
Solid lipid nanoparticles (SLNs) loaded with ibuprofen (IBU) were prepared by solvent-free high-pressure homogenization (HPH). The produced SLNs consisted of stearic acid, triluarin or tripalmitin as lipid matrixes and various stabilizers. The produced empty and IBU-loaded SLNs were characterized for particle size stability over 8 months. Differential scanning calorimetry (DSC) and X-ray diffraction (XRD) were implemented to characterize the IBU state of freeze-dried SLNs. IBU was found to be in both amorphous and crystalline form within the lipid matrix. The lyophilized powders showed increased dissolution rates for IBU depending on the lipid nature. SLNs were incubated in Caco-2 cells for 24?h showing negligible cell cytotoxicity up to 15?mg/mL. 相似文献
10.
为改善布地奈德的溶解度和吸收,制备并评价了布地奈德固体脂质纳米粒(BUD-SLNs)。通过计算部分溶解度参数选择了单硬脂酸甘油酯作为脂材。经处方优化采用乳化-超声分散的方法制备的BUD-SLNs,包封率为(97.77±2.60)%;平均粒径是147.3nm,粒径分布均匀(PDI=0.228)。透射电镜下可见圆整颗粒。差热分析和X射线衍射实验的结果表明BUD以分子形式分散在SLNs中,体外释放结果表明BUD-SLNs符合双相动力学方程,属于均相骨架结构。研究结果为BUD-SLNs在肺部给药奠定了基础。 相似文献
11.
《Journal of microencapsulation》2013,30(1):74-81
Solid lipid nanoparticles (SLNs) loaded with ibuprofen (IBU) were prepared by solvent-free high-pressure homogenization (HPH). The produced SLNs consisted of stearic acid, triluarin or tripalmitin as lipid matrixes and various stabilizers. The produced empty and IBU-loaded SLNs were characterized for particle size stability over 8 months. Differential scanning calorimetry (DSC) and X-ray diffraction (XRD) were implemented to characterize the IBU state of freeze-dried SLNs. IBU was found to be in both amorphous and crystalline form within the lipid matrix. The lyophilized powders showed increased dissolution rates for IBU depending on the lipid nature. SLNs were incubated in Caco-2 cells for 24?h showing negligible cell cytotoxicity up to 15?mg/mL. 相似文献
12.
采用改良的乳化-溶剂挥发法制备齐墩果酸-固体脂质纳米粒(OA-SLNs)并对其性质进行评价。其粒径,zeta电位,包封率和载药率分别为(104.5±11.7)nm,(-25.5±1.8)mV,(94.2±3.9)%,和(4.71±0.15)%。透射电子显微镜下,可见球形实心纳米粒。X-粉末衍射和差示扫描量热(DSC)图谱证实药物分子均匀分散在脂质骨架中。体外释放实验表明,OA-SLNs以每小时4.88%速率缓慢释放药物,符合零级释放动力学模型。OA-SLNs在人工胃液和肠液中具有良好的稳定性。本文研究为OA-SLNs口服给药系统的应用进一步研究提供了可能。 相似文献
13.
目的为芹菜素新型制剂的研究和开发提供实验基础。方法采用热熔超声法制备芹菜素固体脂质纳米粒;以包封率为指标,通过正交试验对处方进行优化。结果制备的纳米粒为类球形,包封率为63.11%,平均粒径为(135±18)nm,zeta电位为-18.90 mV,36 h体外累积释放95.74%。结论热熔超声法可用于制备芹菜素固体脂质纳米粒。 相似文献
14.
目的: 制备槲皮素固体脂质纳米粒并对其理化性质进行考察。方法: 采用乳化蒸发-低温固化法制备槲皮素固体脂质纳米粒,以正交设计优化处方和制备工艺,超滤法测定包封率,透射电子显微镜对其粒子形态进行观察,并使用激光粒度分析仪测定其粒径和Zeta电位。结果: 经处方优化制备的固体脂质纳米粒平均粒径为(124.2±0.371) nm,Zeta电位为(-22.3±0.315) mV,粒子形态均匀,无粘连,平均包封率为(89.3±1.209)%。结论: 制备槲皮素固体脂质纳米粒的工艺简便可行,包封率较高且纳米粒质量优良。 相似文献
15.
目的:微乳法制备固体脂质纳米粒,以酮洛芬作为模型药物,考查其载药性能。方法:通过对空白微乳粒径和稳定性考查,确定优化处方,将其保温分散于冷水中制备固体脂质纳米粒。对影响其质量的工艺因素和处方因素进行考查和优化设计,筛选最优处方。结果:制备固体脂质纳米粒的直接影响因素包括脂质用量、药物的用量、冷水相温度和微乳保温温度等,所得固体脂质纳米粒的平均粒径(143.9±1.2)nm,多分散系数为0.443。载药固体脂质纳米粒包封率为81.47%,载药量为8.16%。结论:该法稳定可靠,可用于酮洛芬固体脂质纳米粒的制备。 相似文献
16.
青藤碱固体脂质纳米粒的制备 总被引:2,自引:0,他引:2
目的:以山嵛酸甘油酯为载体材料制备青藤碱固体脂质纳米粒并评价其质量。方法:采用乳化蒸发一低温固化法制备青藤碱固体脂质纳米粒,以正交设计优化其处方和制备工艺。对其粒径、形态、表面电位、包封率等理化性质进行研究,并考察其稳定性。结果:所制固体脂质纳米粒外观形态圆整,平均粒径为208.7nm,Zeta电位为-38.5mV,平均包封率为65.7%。4℃放置2个月,粒径、包封率无明显变化。结论:青藤碱固体脂质纳米粒的制备,为开发其新制剂奠定了实验基础。 相似文献
17.
Curcuminoid-loaded solid lipid nanoparticles (SLN) were produced by melt-homogenization. The used lipid matrices were medium chain triglycerides, trimyristin and tristearin. The resulting nanoparticles had an anisometric shape and a platelet-like structure. Curcuminoid-loaded trimyristin particles did not solidify when stored at room temperature. The supercooled state of trimyristin was studied by DSC and 1H NMR experiments. A partial recrystallization of the lipid matrix was detected but no change of the mobility of the lipid was noted. Nanoparticles based on tristearin had an α- and β-modification which was subsequently converted into the stable β-phase. Curcuminoids did neither influence the melting behavior nor the crystalline or geometric structure of the particles. The interactions between the curcuminoids and the lipid matrix were investigated by Raman and fluorescence spectroscopy. The shape of the curcuminoid bands in the Raman spectra suggested that the drug was in an amorphous state. The fluorescence spectra showed an effect of the lipid matrix on fluorescence properties of the curcuminoids. It was further demonstrated that the drug was not secluded by the solid lipid matrix, but it was influenced by the surrounding aqueous environment. Fluorescence anisotropy measurements revealed a decreased mobility of the curcuminoids within the nanodispersions. From the results of Raman and fluorescence measurements it was concluded that the drug was mainly located on the surface of the crystalline particles. 相似文献
18.
目的采用超声分散法制备吡喹酮固体脂质纳米粒,并考察制备过程中的主要影响因素。方法首先通过试验确定制备工艺参数,然后考察各处方因素对粒径大小和稳定性的影响,最后以包封率为评价指标,采用正交实验设计法确定最优处方。结果透射电镜测得纳米粒为类圆球状,粒径分布较均匀。动态光散射法测得样品的粒径为(100±21)nm,包封率为(79.3±0.69)%,平均zeta电位值为-66.3 mV。结论以山嵛酸甘油酯和乙酸丁酯为脂质材料,豆磷脂、泊洛沙姆188和硬脂酸钠为复配乳化剂,采用超声分散法可以简便、快速制得吡喹酮固体脂质纳米粒。 相似文献
19.
Soheila Kheradmandnia Ebrahim Vasheghani-Farahani Mohsen Nosrati Fatemeh Atyabi 《Nanomedicine : nanotechnology, biology, and medicine》2010,6(6):753-759
Solid lipid nanoparticles (SLNs) have been proposed as suitable colloidal carriers for delivery of drugs with limited solubility. Ketoprofen as a model drug was incorporated into SLNs prepared from a mixture of beeswax and carnauba wax using Tween 80 and egg lecithin as emulsifiers. The characteristics of the SLNs with various lipid and surfactant composition were investigated. The mean particle size of drug-loaded SLNs decreased upon mixing with Tween 80 and egg lecithin as well as upon increasing total surfactant concentration. SLNs of 75 ± 4 nm with a polydispersity index of 0.2 ± 0.02 were obtained using 1% (vol/vol) mixed surfactant at a ratio of 60:40 Tween 80 to egg lecithin. The zeta potential of these SLNs varied in the range of –15 to –17 (mV), suggesting the presence of similar interface properties. High drug entrapment efficiency of 97% revealed the ability of SLNs to incorporate a poorly water-soluble drug such as ketoprofen. Differential scanning calorimetry thermograms and high-performance liquid chromatographic analysis indicated the stability of nanoparticles with negligible drug leakage after 45 days of storage. It was also found that nanoparticles with more beeswax content in their core exhibited faster drug release as compared with those containing more carnauba wax in their structure.From the Clinical EditorKetoprofen as model drug was incorporated into solid lipid nanoparticles, which have been proposed as suitable colloidal carriers for delivery of drugs with limited solubility. High drug entrapment efficiency, stability of nanoparticles with negligible drug leakage and fast drug release can be accomplished using this technology. 相似文献
20.
A solvent emulsification evaporation method was employed to prepare solid lipid nanoparticles (SLN) loaded with syringopicroside. The conventional broad-spectrum antibacterial and antiviral drug syringopicroside was incorporated into SLN to improve drug targeting. The SYR-SLNs were spherical and uniform in transmission electron microscopy (TEM). The mean particle size and potential were 180.31 +/- 10 nm, and -41.9 +/- 10.3 mV, respectively. Also, a sephadex column chromatography was adopted to investigate the encapsulation efficiency (EE %) of the SLN. This method is based on the principle of molecular sieve effect, and the EE% of the optimal formulation was 42.35 %. Drug-loading capacity was 5.33 %. The in vitro release profile revealed that syringopicroside was released from SLN efficiently and completely in normal saline (NS) compared with other release media. A HPLC method was established for in vivo assay of syringopicroside. A tissue distribution study was conducted in rats after iv administration of 15 mg/kg SYR-SLN and syringopicroside NS, and it was found that SYR-SLN has improved delivery to the liver compared with any other organizations. These results indicated that solvent emulsification evaporation is a simple, easy, available and effective method for preparing SYR-SLN. 相似文献